In this study, we have demonstrated that ASA prodrugs with ancillary pharmacophores can be effectively used to inhibit NFκB activity in breast cancer cells, whereas ASA itself was ineffective at much higher concentrations. The gene discussed is NFKB1; the disease is breast carcinoma.